Clinical Trials in Haikou, Hainan

1 recruiting

Showing 115 of 15 trials

Recruiting
Phase 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

OncoC4, Inc.630 enrolled152 locationsNCT05671510
Recruiting
Phase 1Phase 2

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Lung CancerPancreas CancerThyroid Cancer+1 more
Sichuan Enray Pharmaceutical Sciences Company54 enrolled9 locationsNCT07433283
Recruiting
Phase 3

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Phase 3

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled69 locationsNCT07047365
Recruiting
Phase 3

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Summit Therapeutics1,600 enrolled244 locationsNCT05899608
Recruiting
Phase 2Phase 3

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Not Applicable

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

Breast Cancers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University112 enrolled9 locationsNCT07095023
Recruiting
Phase 3

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.246 enrolled31 locationsNCT07008976
Recruiting
Not Applicable

Topical Diclofenac for Prevention of Radiation-induced Dermatitis

Breast CancerHead and Neck Tumor
The Second Affiliated Hospital of Hainan Medical University156 enrolled1 locationNCT06905561
Recruiting
Phase 3

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.518 enrolled71 locationsNCT05922345
Recruiting

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Liver CancerPancreatic CancerGastric Cancer+8 more
Zhujiang Hospital12,000 enrolled50 locationsNCT05638269
Recruiting
Phase 3

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.522 enrolled86 locationsNCT06300177
Recruiting
Phase 3

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Breast Cancer
Genor Biopharma Co., Ltd.350 enrolled52 locationsNCT05851014
Recruiting
Phase 1Phase 2

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd.183 enrolled44 locationsNCT04270591